Systemic reactions to house dust mite subcutaneous immunotherapy in patients with allergic rhinitis and/or asthma: A real‐life, multi‐center study

作者：Qingxiu Xu, Jiaxin Jia, Hang Lin, Dan Liang, Hao Chen, Yin Wang, Xiang Gao, Wang Liao, Guohua Chen, Lihong Yang, Qianlan Zhou, Jun Bai, Zhihai Xie, Lishen Shan, Rongfei Zhu · 发表于：Allergy · 年份：2024 · DOI：10.1111/all.16254 · 被引用次数：7 · 研究领域：Allergic Rhinitis and Sensitization、Asthma and respiratory diseases、Dermatology and Skin Diseases

Subcutaneous immunotherapy (SCIT) has demonstrated significant efficacy in treating respiratory allergies, such as reducing allergic symptoms and the need for medication, preventing progression toward asthma, reducing new sensitization, and providing long-term efficacy after treatment cessation. Since it is often associated with systemic reactions (SRs) that can pose potential life-threatening risks, it is crucial to identify and mitigate potential risk factors to prevent SRs during SCIT. Previous studies have highlighted the substantial impact of allergen extract quality on SCIT safety. As commercial allergen products vary in protein content, concentration, and biological activity, the World Allergy Organization (WAO) emphasizes the necessity for each allergen product to possess individual data on clinical efficacy and safety, establishing product-specific evidence-based medical validation.1 In China, house dust mite (HDM) stands as the most prevalent allergen triggering respiratory allergies.2 NHD (Novo-HELISEN-Depot, NHD, Reinbeck, Germany), a standardized subcutaneous formulation, has been widely employed in China for treating respiratory allergies. In this large-scale retrospective multicenter study, we investigated the safety and risk factors for SRs during NHD SCIT in patients diagnosed with HDM-induced allergic rhinitis (AR) and/or asthma according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines and the Global Initiative for Asthma (GINA) guideline...